A multi-center, randomized, double-blind and positive parallel control clinical study of the efficacy and safety of Levornidazole Disodium Phosphate for Injection in the treatment of pelvic anaerobic infections

Start Date15 May 2018

Sponsor / Collaborator

Third Affiliated Hospital of Nanjing Medical University

ChiCTR2300070768 / CompletedPhase 1IIT

A pharmacokinetics study of levornidazole sodium chloride injection and ornidazole sodium chloride injection in healthy volunteers

Start Date03 May 2017

Sponsor / Collaborator

Beijing Hospital of the Ministry of Health

CTR20160786 / CompletedPhase 1

中国健康受试者单/多次口服左奥硝唑片的安全性、耐受性和药动学研究及口服左奥硝唑片500mg绝对生物利用度研究

[Translation] Safety, tolerability and pharmacokinetics of single/multiple oral administration of levonidazole tablets and absolute bioavailability of 500 mg oral levonidazole tablets in Chinese healthy subjects

试验目的是通过中国健康受试者单次、多次以及高脂餐后口服左奥硝唑片，评价左奥硝唑片在受试者中的安全性、耐受性和药物代谢动力学特征，通过口服左奥硝唑片500mg和静脉滴注左奥硝唑氯化钠注射液500mg的PK研究，评价左奥硝唑片的绝对生物利用度。为临床治疗方案的制定提供依据。

[Translation]

The purpose of the trial is to evaluate the safety, tolerability and pharmacokinetic characteristics of levonidazole tablets in Chinese healthy subjects by taking them orally once, multiple times and after a high-fat meal, and to evaluate the absolute bioavailability of levonidazole tablets by a PK study of oral levonidazole tablets 500 mg and intravenous infusion of levonidazole sodium chloride injection 500 mg, so as to provide a basis for the formulation of clinical treatment plans.

Start Date15 Dec 2016

Sponsor / Collaborator

Nanjing Sanhome Pharmaceutical Co. Ltd.

100 Clinical Results associated with Levornidazole

100 Translational Medicine associated with Levornidazole

100 Patents (Medical) associated with Levornidazole

Literatures (Medical) associated with Levornidazole

01 Dec 2023·Int. Journal of Clinical Pharmacology and Therapeutics

Pharmacokinetics and safety of injected ornidazole compared to its enantiomer levornidazole in healthy Chinese subjects

Article

Author: Tang, Kaitian ; Li, Kexin ; Bai, Wenjing ; Wang, Tingting ; Liu, Yao ; Zhang, Ying ; Wang, Xin ; Qin, Jie ; Xue, Wei ; Wang, Juan ; Liu, Yue

OBJECTIVETo compare the pharmacokinetics of levornidazole and ornidazole in healthy Chinese subjects after a single intravenous injection, and to determine whether the chiral inversion of levornidazole occurs in vivo.MATERIALS AND METHODSThe study was a randomized, open-label, two-period crossover, single-dose design. A total of 12 subjects were enrolled in this study. Subjects received an intravenous injection of either levornidazole sodium chloride injection (200 mL: 0.5 g) or ornidazole sodium chloride injection (200 mL: 0.5 g) once per period. The plasma concentrations of levornidazole, ornidazole, and their metabolites were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Phenix WinNolin software (version 6.4) was used to calculate the pharmacokinetic parameters of levornidazole, ornidazole, and their metabolites.RESULTSDexornidazole was not detected in the plasma or urine. After a single intravenous injection of levornidazole or ornidazole, there was no significant difference in C_max between the two drugs (p < 0.05). The AUC_0-∞ and AUC_0-t of levornidazole were slightly lower than those of ornidazole. Metabolites M1 and M4 were detected in the plasma of both drugs, and their pharmacokinetic parameters were similar. Metabolites M1, M2, and M4 were present in urine. The average cumulative urinary excretion rates of levornidazole and its metabolites M1 and M4 were: during 0 - 24 hours (8.14 ± 0.80%, 0.560 ± 0.072%, and 1.42 ± 0.19%) and 0 - 60 hours (10.5 ± 1.0%, 0.960 ± 0.084%, and 2.52 ± 0.20%), the average cumulative urinary excretion rates of ornidazole and its metabolites M1 and M4 were: 0 - 24 hours (8.64 ± 0.98%, 0.486 ± 0.074%, and 1.46 ± 0.21%), 0 - 60 hours (11.8 ± 1.0%, 0.888 ± 0.070%, and 2.76 ± 0.20%). The incidence of adverse reactions was similar between the two drugs.CONCLUSIONNo chiral inversion of levornidazole occurred in vivo after intravenous administration of levornidazole. The pharmacokinetic parameters and cumulative excretion rates of levornidazole and ornidazole were similar. The safety results were basically consistent between the two drugs.

01 Apr 2023·International Journal of Antimicrobial Agents

Population pharmacokinetics of levornidazole in healthy subjects and patients, and sequential dosing regimen proposal using pharmacokinetic/pharmacodynamic analysis

Article

Author: Zhang, Jing ; Cao, Yuran ; Yu, Jicheng ; Wu, Hailan ; Guo, Beining ; Fan, Yaxin ; Cao, Guoying ; Li, Yi ; Wu, Xiaojie

Although sequential treatment with levornidazole has been used for anaerobic infection in clinical practice, there is no evidence-based dosing regimen. This study aimed to evaluate the pharmacokinetics (PK) of levornidazole in healthy subjects and patients, and to propose an evidence-based sequential dosing regimen by pharmacokinetic/pharmacodynamic (PK/PD) analysis. A population PK model was built using the data of 116 Chinese subjects, including 88 healthy young subjects, 12 healthy elderly subjects, and 16 patients with intra-abdominal anaerobic infection. PK/PD analysis was performed combining the minimum inhibitory concentration (MIC) values of levornidazole against 375 anaerobic strains. Four sequential dosing regimens (500 mg q12h, 1000 mg loading dose followed by 500 mg q12h, 750 mg q24h, and 1000 mg q24h) were evaluated in terms of cumulative fraction of response (CFR) and probability of target attainment (PTA) by Monte Carlo simulation. The concentration data of levornidazole and its active metabolites were described adequately by two- and one-compartment models, respectively. Body weight was identified as a significant covariate of levornidazole clearance. Simulations showed that satisfactory PTA (>90%) was achieved for the four dosing regimens when MIC ≤1 mg/L. Considering the simulation results, patients' safety and compliance, levornidazole 750 mg intravenous infusion q24h for 2 days followed by 750 mg oral dose q24h for 5 days was optimal for Bacteroides spp. with an identified MIC ≤1 mg/L.

01 Aug 2021·Current Medical ScienceQ4 · MEDICINE

The Potential Immunomodulatory Properties of Levornidazole Contribute to Improvement in Experimental Ulcerative Colitis

Q4 · MEDICINE

Article

Author: Xie, Jun ; Yao, Rui-Qin ; Gou, Ling-Shan ; Huang, Yan-Xiu ; Chen, Hao ; Zhang, Rui-Juan ; Li, Yu ; Huang, Yu-Qing ; Wang, Xing-Qi ; Gao, Yu-Zhi

The use of an antibiotic with immunomodulatory properties could be fascinating in treating multifactorial inflammatory conditions such as ulcerative colitis (UC). We report our investigations into the immunomodulatory properties of levornidazole, the S-enantiomer of ornidazole, which displayed a tremendous therapeutic potential in UC induced by dextran sodium sulfate (DSS). Levornidazole administration to DSS-colitic mice attenuated the intestinal inflammatory process, with an efficacy better than that shown by 5-amino salicylic acid. This was evidenced by decreased disease activity index, ameliorated macroscopic and microscopic colon damages, and reduced expression of inflammatory cytokines. Additionally, levornidazole displayed anti-inflammatory activity through Caveolin-1-dependent reducing IL-1β and IL-18 secretion by macrophages contributing to its improvement of the intestinal inflammation, as confirmed in vitro and in vivo. In conclusion, these results pointed out that the immunomodulatory effects of levornidazole played a vital role in ameliorating the intestinal inflammatory process, which would be crucial for the translation of its use into clinical settings.

100 Deals associated with Levornidazole

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J01	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	CN	Nanjing Sanhome Pharmaceutical Co. Ltd.	14 Aug 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis